FEVAR is an established customized treatment for aortic aneurysms with three current
commercially available configurations for the superior mesenteric artery (SMA) – a
single-wide scallop, large fenestration, or small fenestration, with the scallop or
large fenestration most utilized. Outcomes comparing SMA single-wide scallops to large
fenestrations with the ZFEN device are scarce. As large fenestrations have the benefit
of extending the proximal seal zone compared to scalloped configurations, we sought
to determine the differences in seal zone and sac regression outcomes between the
two SMA configurations.
We retrospectively reviewed our prospectively maintained complex EVAR database and
included all patients treated with the Cook ZFEN device with an SMA scallop or large
fenestration configuration at its most proximal build. All first post-operative CT
scans (1-30 days) were analyzed on TeraRecon to determine precise proximal seal zone
lengths, and standard follow-up anatomic and clinical metrics were tabulated.
A total of 234 consecutive ZFEN patients from 2012-2021 were reviewed, and 137 had
either a scallop or large fenestration for the SMA as the proximal-most configuration
(72 scallops and 65 large fenestrations) with imaging available for analysis. Mean
follow-up was 35 months. Mean proximal seal zone length was 19.5±7.9 mm for scallop
vs 41.7±14.4 mm for large fenestration groups (P<.001). There was no difference in
sac regression between scallop and large fenestration at one year (10.1±10.9 mm vs
11.0±12.1, P = 0.63). Overall, 30-day mortality (1.3% vs 2.5%, P=.51) and all-cause
three-year mortality (72.5% vs 81.7%, P=.77) were not significantly different. Reinterventions
within 30 days were primarily secondary to renal artery branch occlusions, with only
one patient in the scallop group requiring reintervention for an SMA branch occlusion.
Despite attaining longer proximal seal lengths, large SMA fenestrations were not associated
with a difference in sac regression compared to scalloped SMA configurations at one-year
follow up. There were no significant differences in reinterventions or overall long-term
survival between the two SMA strategies.